ifosfamide has been researched along with bortezomib in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 10 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ding, L; Duan, LN; Liu, J; Wang, HX; Wang, ZD; Xue, M; Yan, HM; Zhu, L | 1 |
| Farid, M; Koo, GC; Lim, ST; Loong, S; Quek, R; Tao, M; Tay, K; Yau, YW | 1 |
| Anderlini, P; Fanale, M; Fayad, L; Horowitz, S; Ji, Y; Kwak, LW; Liboon, MJ; Nunez, C; Popat, U; Pro, B; Samaniego, F; Younes, A | 1 |
| Andemariam, B; Coleman, M; Elstrom, RL; Furman, RR; Leonard, JP; Martin, P; Ruan, J; Shore, TB | 1 |
| Agrawal, N; Buxton, A; Chen, L; Cole, PD; De Alarcon, PA; Drachtman, RA; Guillerman, RP; Hogan, SM; Horton, TM; Howard, SC; Liu, H; López-Terrada, D; McCarten, K; Mrazek, MD; Schwartz, CL; Sheehan, AM; Trippet, TM; Voss, S; Wu, MF | 1 |
| Anastasia, A; Angelucci, E; Annechini, G; Balzarotti, M; Bonfichi, M; Botto, B; Brusamolino, E; Carella, AM; Congiu, A; Giordano, L; Gotti, M; Magagnoli, M; Massidda, S; Mazza, R; Merli, F; Murru, R; Re, A; Rodari, M; Russo, E; Salvi, F; Santoro, A; Spina, M; Stelitano, C; Vitolo, U; Zilioli, VR | 1 |
| An, N; Huang, ZX; Li, X; Shen, M; Sun, WJ; Zhang, JJ | 1 |
| Aboulafia, D; Ambinder, RF; Cesarman, E; Henry, D; Lee, J; Looney, D; Maldarelli, F; Mitsuyasu, R; Noy, A; Ramos, JC; Reid, EG; Sparano, J; Wachsman, W; Yahyaei, S | 1 |
1 review(s) available for ifosfamide and bortezomib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 trial(s) available for ifosfamide and bortezomib
| Article | Year |
|---|---|
Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carboplatin; Disease-Free Survival; Etoposide; Hodgkin Disease; Humans; Ifosfamide; Pyrazines; Recurrence; Treatment Outcome; Young Adult | 2011 |
Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Cisplatin; Combined Modality Therapy; Dexamethasone; Disease-Free Survival; Etoposide; Humans; Ifosfamide; Immunotherapy; Lymphoma, Large B-Cell, Diffuse; Middle Aged; Proteasome Endopeptidase Complex; Pyrazines; Recurrence; Rituximab; Time Factors; Treatment Outcome | 2012 |
A phase 2 study of bortezomib in combination with ifosfamide/vinorelbine in paediatric patients and young adults with refractory/recurrent Hodgkin lymphoma: a Children's Oncology Group study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Child; Child, Preschool; Disease-Free Survival; Hodgkin Disease; Humans; Ifosfamide; Neoplasm Recurrence, Local; Pyrazines; Vinblastine; Vinorelbine; Young Adult | 2015 |
B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL).
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Combined Modality Therapy; Deoxycytidine; Drug Resistance, Neoplasm; Female; Gemcitabine; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Middle Aged; Neoplasm Staging; Recurrence; Remission Induction; Survival Analysis; Transplantation, Autologous; Treatment Outcome; Vinblastine; Vinorelbine; Young Adult | 2016 |
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; APOBEC-3G Deaminase; Bortezomib; Carboplatin; Etoposide; Female; HIV; HIV Infections; Humans; Ifosfamide; Leukocytes, Mononuclear; Lymphoma; Male; Middle Aged; Oncolytic Virotherapy; Recurrence; Rituximab; Viral Load | 2018 |
6 other study(ies) available for ifosfamide and bortezomib
| Article | Year |
|---|---|
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Bortezomib in combination with IGEV chemotherapy regimen for a primary refractory Hodgkin's lymphoma of bone.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Boronic Acids; Bortezomib; Combined Modality Therapy; Deoxycytidine; Gemcitabine; Hematopoietic Stem Cell Transplantation; Hodgkin Disease; Humans; Ifosfamide; Male; Positron-Emission Tomography; Prednisone; Pyrazines; Vinblastine; Vinorelbine | 2009 |
A promising new regimen for the treatment of advanced extranodal NK/T cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Female; Gemcitabine; Humans; Ifosfamide; Lymphoma, Extranodal NK-T-Cell; Lymphoma, T-Cell; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Treatment Outcome | 2011 |
Clinical analysis of 40 multiple myeloma patients with extramedullary plasmacytoma of the head.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Dexamethasone; Disease Progression; Doxorubicin; Female; Head and Neck Neoplasms; Humans; Ifosfamide; Male; Middle Aged; Multiple Myeloma; Plasma Cells; Plasmacytoma; Prognosis; Prospective Studies; Survival Analysis | 2016 |